Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Anna Spreafico

Showing results (21-30 of 186) with videos related to

Pageof 19
Sort By:
Cancer|June 30, 2007
Prognostic value of circulating chromogranin A and soluble tumor necrosis factor receptors in advanced nonsmall cell lung cancerVanesa Gregorc, Anna Spreafico, Irene Floriani, et al.
Cancers|January 26, 2024
The Clinical, Genomic, and Transcriptomic Landscape of BRAF Mutant CancersSuzanne Kazandjian, Emmanuelle Rousselle, Matthew Dankner, et al.
Current Oncology (Toronto, Ont.)|July 2, 2021
Real World Outcomes and Hepatotoxicity of Infliximab in the Treatment of Steroid-Refractory Immune-Related Adverse EventsDaniel V Araujo, Thiago Pimentel Muniz, Anjie Yang, et al.
The Oncologist|February 8, 2019
Feasibility Assessment of Using the Complete Patient-Reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) Item LibraryDaniel Shepshelovich, Kate McDonald, Anna Spreafico, et al.
European Heart Journal. Case Reports|January 26, 2022
Immune checkpoint inhibitor-related myocarditis: an illustrative case series of applying the updated Cardiovascular Magnetic Resonance Lake Louise CriteriaBernd J Wintersperger, Oscar Calvillo-Argüelles, Stephanie Lheureux, et al.
The Oncologist|March 6, 2019
Referrals to a Phase I Clinic and Trial Enrollment in the Molecular Screening EraTira Tan, Michael Rheaume, Lisa Wang, et al.
Cancer Chemotherapy and Pharmacology|November 10, 2019
Characterization and outcomes of patients enrolled to multiple phase I cancer trialsNathan Kuehne, Lina Chen, Kate McDonald, et al.
Journal of the National Cancer Institute|December 7, 2006
Pharmacogenetics of ABCG2 and adverse reactions to gefitinibGeorge Cusatis, Vanesa Gregorc, Jing Li, et al.
Msystems|July 13, 2021
Two-Target Quantitative PCR To Predict Library Composition for Shallow Shotgun SequencingMatthew Y Cho, Marc Oliva, Anna Spreafico, et al.
Plos One|June 11, 2021
Evaluation of liver enzyme elevations and hepatotoxicity in patients treated with checkpoint inhibitor immunotherapyMorven Cunningham, Marco Iafolla, Yada Kanjanapan, et al.
Pageof 19

Showing results (21-30 of 186) with videos related to

Sort By:
Pageof 19
Cancer|June 30, 2007
Prognostic value of circulating chromogranin A and soluble tumor necrosis factor receptors in advanced nonsmall cell lung cancerVanesa Gregorc, Anna Spreafico, Irene Floriani, et al.
Cancers|January 26, 2024
The Clinical, Genomic, and Transcriptomic Landscape of BRAF Mutant CancersSuzanne Kazandjian, Emmanuelle Rousselle, Matthew Dankner, et al.
Current Oncology (Toronto, Ont.)|July 2, 2021
Real World Outcomes and Hepatotoxicity of Infliximab in the Treatment of Steroid-Refractory Immune-Related Adverse EventsDaniel V Araujo, Thiago Pimentel Muniz, Anjie Yang, et al.
The Oncologist|February 8, 2019
Feasibility Assessment of Using the Complete Patient-Reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) Item LibraryDaniel Shepshelovich, Kate McDonald, Anna Spreafico, et al.
European Heart Journal. Case Reports|January 26, 2022
Immune checkpoint inhibitor-related myocarditis: an illustrative case series of applying the updated Cardiovascular Magnetic Resonance Lake Louise CriteriaBernd J Wintersperger, Oscar Calvillo-Argüelles, Stephanie Lheureux, et al.
The Oncologist|March 6, 2019
Referrals to a Phase I Clinic and Trial Enrollment in the Molecular Screening EraTira Tan, Michael Rheaume, Lisa Wang, et al.
Cancer Chemotherapy and Pharmacology|November 10, 2019
Characterization and outcomes of patients enrolled to multiple phase I cancer trialsNathan Kuehne, Lina Chen, Kate McDonald, et al.
Journal of the National Cancer Institute|December 7, 2006
Pharmacogenetics of ABCG2 and adverse reactions to gefitinibGeorge Cusatis, Vanesa Gregorc, Jing Li, et al.
Msystems|July 13, 2021
Two-Target Quantitative PCR To Predict Library Composition for Shallow Shotgun SequencingMatthew Y Cho, Marc Oliva, Anna Spreafico, et al.
Plos One|June 11, 2021
Evaluation of liver enzyme elevations and hepatotoxicity in patients treated with checkpoint inhibitor immunotherapyMorven Cunningham, Marco Iafolla, Yada Kanjanapan, et al.
Pageof 19